Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

Use of zoledronic acid in the treatment of Paget’s disease

Authors Margaret Seton, Stephen M Krane

Published 15 November 2007 Volume 2007:3(5) Pages 913—918

Margaret Seton1, Stephen M Krane2

1,2Division of Rheumatology, Allergy and Immunology; 2Center for Immunology and Inflammatory Diseases, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, MA, USA

Abstract: This review examines the use of zoledronic acid in the treatment of Paget’s disease of bone. It begins with a brief discussion of the theories of pathogenesis of Paget’s disease, its clinical manifestations, and the history of bisphosphonate treatment in this disorder. Risk of oversuppression of bone by the more potent bisphosphonates and their association with avascular necrosis of the jaw are noted.

Keywords: Paget’s disease of bone, bisphosphonates, zoledronic acid

Download Article [PDF] 

Readers of this article also read:

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer

Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Chin K, Yamaguchi T

Drug Design, Development and Therapy 2015, 9:1653-1662

Published Date: 16 March 2015

Association between homocysteinemia and metabolic syndrome in patients with cardiovascular disease

Chiara Bellia, Giulia Bivona, Concetta Scazzone, Marcello Ciaccio

Therapeutics and Clinical Risk Management 2007, 3:999-1001

Published Date: 15 January 2008

Treatment of atopic dermatitis with pimecrolimus – impact on quality of life

Hae-Hyuk Lee, Torsten Zuberbier, Margitta Worm

Therapeutics and Clinical Risk Management 2007, 3:1021-1026

Published Date: 15 January 2008

A critical analysis of barriers to the clinical implementation of pharmacogenomics

Ross A McKinnon, Michael B Ward, Michael J Sorich

Therapeutics and Clinical Risk Management 2007, 3:751-759

Published Date: 15 November 2007

A systematic review of infliximab in the treatment of early rheumatoid arthritis

Sophie Martin Du Pan, Cem Gabay, Axel Finckh

Therapeutics and Clinical Risk Management 2007, 3:905-911

Published Date: 15 November 2007